Method for simultaneously detecting central demyelinating autoantibodies AQP4, MOG and MBP

Abstract

The invention discloses a method for simultaneously detecting central demyelinating autoantibodies AQP4, MOG and MBP. The method comprises the following steps of respectively introducing AQP4, MOG andMBP genes into HEK293T cells, respectively incubating the AQP4, MOG and MBP genes together with a sample to be detected, detecting by adopting an immunofluorescence method and taking the HEK293T cells transfected with an empty carrier as a contrast, and determining that the sample to be detected is positive if a fluorescence signal is stronger than the contrast; and determining that the sample tobe detected is negative if the fluorescence signal is equal to or smaller than the control signal. The invention provides the method for simultaneously detecting central demyelinating autoantibodiesAQP4, MOG and MBP in a same system, a fluorescence immunocyte staining technology with higher sensitivity and specificity is used for clinically and qualitatively detecting AQP4, MOG and MBP antibodies, so that the detection result is more stable, and the labor and time costs are greatly saved.

Description

[0001] (1) Technical field [0002] The invention relates to a detection of central demyelinating autoantibodies, in particular to a method for simultaneously detecting central demyelinating autoantibodies AQP4, MOG and MBP. [0003] (2) Background technology [0004] Demyelinating disease of the central nervous system is an autoimmune disease mainly characterized by multifocal and inflammatory demyelination of the central nervous system, and its clinical features mainly include recurrent attacks, multiple remissions and relapses. The more common clinical demyelinating diseases of the central nervous system include multiple sclerosis (Multiple Sclerosis, MS), neuromyelitis optica (neuromyelitis optica, NMO), acute disseminated encephalomyelitis and so on. In recent years, the incidence of central nervous system demyelinating diseases has been increasing year by year, which has a serious impact on the quality of life of patients and poses a serious threat to patients' physical a...

AI Technical Summary

Problems solved by technology

It takes a long time, consumes a lot of manpower and material resources, and the fluorescence efficiency is unstable. A more stable transfection method is needed to obtain more sensitive and stable results.

The detection of MOG and MBP autoantibodies mostly uses nerve tissue sections with high expression of MBP antigen for staining and detection. There are many problems in this method, such as the difficulty in controlling the location of sectioned tissues, resulting in large differences between batches; most of the tissue sections are of animal origin (such as Monkey nerve tissue slices used by European companies), there are species differences in antigens, which reduce the sensitivity and specificity of detection; there are other antigens except MBP in the tissue, and the positive result of the test may not be positive for MBP antibody

2. Western or Elisa method detection, although the two technologies are relatively mature, but because it is difficult to maintain the spatial conformation of the MBP antigen, its specificity is not high, and the cost is expensive, which greatly limits the promotion of these detection methods

Images